Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Glycomimetics Inc (GLYC)

Glycomimetics Inc (GLYC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 110,209
  • Shares Outstanding, K 64,450
  • Annual Sales, $ 10 K
  • Annual Income, $ -36,900 K
  • 60-Month Beta 2.18
  • Price/Sales 11,955.47
  • Price/Cash Flow N/A
  • Price/Book 3.02
Trade GLYC with:

Options Overview Details

View History
  • Implied Volatility 423.30% ( +20.08%)
  • Historical Volatility 85.08%
  • IV Percentile 93%
  • IV Rank 47.65%
  • IV High 820.87% on 10/11/23
  • IV Low 61.38% on 03/05/24
  • Put/Call Vol Ratio 1.44
  • Today's Volume 1,026
  • Volume Avg (30-Day) 3,490
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 85,494
  • Open Int (30-Day) 61,065

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.15
  • Number of Estimates 2
  • High Estimate -0.14
  • Low Estimate -0.15
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +11.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6950 +0.88%
on 04/25/24
3.1800 -46.23%
on 03/27/24
-1.1100 (-39.36%)
since 03/25/24
3-Month
1.6950 +0.88%
on 04/25/24
3.5000 -51.14%
on 01/29/24
-1.4500 (-45.89%)
since 01/25/24
52-Week
1.1100 +54.05%
on 10/25/23
3.5299 -51.56%
on 01/23/24
+0.3400 (+24.82%)
since 04/25/23

Most Recent Stories

More News
GlycoMimetics: Q4 Earnings Snapshot

GlycoMimetics: Q4 Earnings Snapshot

GLYC : 1.7100 (-7.82%)
GlycoMimetics: Q3 Earnings Snapshot

GlycoMimetics: Q3 Earnings Snapshot

GLYC : 1.7100 (-7.82%)
GlycoMimetics: Q2 Earnings Snapshot

GlycoMimetics: Q2 Earnings Snapshot

GLYC : 1.7100 (-7.82%)
GlycoMimetics: Q1 Earnings Snapshot

GlycoMimetics: Q1 Earnings Snapshot

GLYC : 1.7100 (-7.82%)
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023

GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial...

GLYC : 1.7100 (-7.82%)
GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2023 financial results on Wednesday, May 3, 2023, at 8:30 a.m. ET.

GLYC : 1.7100 (-7.82%)
GlycoMimetics: Q4 Earnings Snapshot

GlycoMimetics: Q4 Earnings Snapshot

GLYC : 1.7100 (-7.82%)
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022

GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial...

GLYC : 1.7100 (-7.82%)
GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2022 full year financial results on Wednesday, March 29, 2023, at 8:30 a.m....

GLYC : 1.7100 (-7.82%)
GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 43 rd Annual Health Care Conference in Boston, MA...

GLYC : 1.7100 (-7.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at...

See More

Key Turning Points

3rd Resistance Point 1.8975
2nd Resistance Point 1.8540
1st Resistance Point 1.7820
Last Price 1.7100
1st Support Level 1.6665
2nd Support Level 1.6230
3rd Support Level 1.5510

See More

52-Week High 3.5299
Fibonacci 61.8% 2.6055
Fibonacci 50% 2.3200
Fibonacci 38.2% 2.0344
Last Price 1.7100
52-Week Low 1.1100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar